Exelixis and Boehringer Ingelheim join forces to develop autoimmune disease therapies
US-based Exelixis and German pharmaceutical group Boehringer Ingelheim are collaborating on therapies targeted at autoimmune diseases therapies. The collaboration is focused on the discovery of sphingosine-1-phosphate type 1 receptor (S1P1) agonists. The S1P1 receptor is a central mediator of multiple pathways implicated in a variety of autoimmune diseases.
US-based Exelixis and German pharmaceutical group Boehringer Ingelheim are collaborating on therapies targeted at autoimmune diseases therapies. The collaboration is focused on the discovery of sphingosine-1-phosphate type 1 receptor (S1P1) agonists. The S1P1 receptor is a central mediator of multiple pathways implicated in a variety of autoimmune diseases.
Under the terms of the agreement, Exelixis will receive a US$15m upfront payment, followed by a potential of up to $339m in milestone payments.
The two companies will share responsibility for discovery activities and Boehringer will in addition have sole responsibility for all subsequent pre-clinical, clinical, regulatory, commercial and manufacturing activities.
